- Home
- NXL vs USBC Comparison
NXL vs USBC Comparison
Compare NXL & USBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXL
- USBC
- Stock Information
- Founded
- NXL 2010
- USBC N/A
- Country
- NXL United States
- USBC
- Employees
- NXL N/A
- USBC N/A
- Industry
- NXL Medical Specialities
- USBC
- Sector
- NXL Health Care
- USBC
- Exchange
- NXL Nasdaq
- USBC Nasdaq
- Market Cap
- NXL 14.0M
- USBC 14.5M
- IPO Year
- NXL 2022
- USBC N/A
- Fundamental
- Price
- NXL $0.85
- USBC $0.74
- Analyst Decision
- NXL Strong Buy
- USBC
- Analyst Count
- NXL 1
- USBC 0
- Target Price
- NXL $5.00
- USBC N/A
- AVG Volume (30 Days)
- NXL 2.9M
- USBC N/A
- Earning Date
- NXL 11-07-2025
- USBC N/A
- Dividend Yield
- NXL N/A
- USBC N/A
- EPS Growth
- NXL N/A
- USBC N/A
- EPS
- NXL N/A
- USBC N/A
- Revenue
- NXL $174,813.00
- USBC N/A
- Revenue This Year
- NXL $38.28
- USBC N/A
- Revenue Next Year
- NXL $185.71
- USBC N/A
- P/E Ratio
- NXL N/A
- USBC N/A
- Revenue Growth
- NXL 16.42
- USBC N/A
- 52 Week Low
- NXL $0.59
- USBC N/A
- 52 Week High
- NXL $4.49
- USBC N/A
- Technical
- Relative Strength Index (RSI)
- NXL 46.92
- USBC N/A
- Support Level
- NXL $0.79
- USBC N/A
- Resistance Level
- NXL $0.99
- USBC N/A
- Average True Range (ATR)
- NXL 0.08
- USBC 0.00
- MACD
- NXL 0.01
- USBC 0.00
- Stochastic Oscillator
- NXL 32.38
- USBC 0.00
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.